ROCHE HOLDING LTD S/ADR - RHHBY STOCK NEWS

Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.

Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.

08/29/2023 01:00 AM

News

European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)

Rhea-AI Summary

Roche's Evrysdi receives EU approval for treating SMA in all ages, including babies from birth

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.34%

Tags

08/23/2023 01:43 AM

News

Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary

Genentech (RO, ROG; RHHBY) inadvertently discloses interim analysis of SKYSCRAPER-01 study on tiragolumab plus Tecentriq for NSCLC treatment. Overall survival estimates: 22.9 months in tiragolumab plus Tecentriq arm, 16.7 months in Tecentriq monotherapy arm. No new safety signals found.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.34%

Tags

08/23/2023 01:22 AM

News

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

Rhea-AI Summary

Roche (RO, ROG; RHHBY) has disclosed the second interim analysis of the Phase III SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq as a first-line treatment for NSCLC. The study remains blinded and ongoing. The interim results showed a median overall survival of 22.9 months for tiragolumab plus Tecentriq and 16.7 months for Tecentriq alone, with a hazard ratio of 0.81. No new safety signals were identified.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.34%

Tags

08/17/2023 01:00 AM

News

Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency

Rhea-AI Summary

Roche has announced the extension of its cobas® connection modules (CCM) sample conveyors system with the newly developed CCM Vertical, allowing transportation of samples on overhead conveyors. This modular and flexible solution optimizes laboratory space and enables the transport of samples to adjacent floors or rooms, addressing the space limitations in laboratories.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.35%

Tags

08/08/2023 01:00 AM

News

New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.24%

Tags

08/03/2023 01:00 AM

News

Roche expands long-term alliance with Sysmex

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.63%

Tags

07/27/2023 01:00 AM

News

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products

Rhea-AI Summary

Roche Group reports strong sales growth in Pharmaceuticals Division and decline in Diagnostics Division due to lower demand for COVID-19 tests. Core earnings per share and IFRS net income decrease. Important pipeline milestones reached. Outlook for 2023 confirmed.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.72%

Tags

07/24/2023 01:00 AM

News

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

Rhea-AI Summary

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Hypertension affects over 1.2 billion adults worldwide and is a leading cause of cardiovascular disease. Zilebesiran has the potential to be a best-in-disease treatment, with positive Phase 1 data showing dose-dependent reductions in blood pressure. The partnership will allow both companies to pursue joint development and commercialization, with Roche obtaining exclusive commercialization rights outside the US. Alnylam will receive an upfront payment of $310 million and will share costs and profits equally with Roche in the US.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.38%

Tags

07/21/2023 09:30 AM

News

CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.79%

Tags

07/20/2023 01:00 AM

News

New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.23%

Tags

FAQ

What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?

The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35.44 as of November 22, 2024.

What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?

The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 230.4B.

What is Roche Holdings Ltd. S/ADR (RHHBY) known for?

Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.

What is the significance of Columvi® (glofitamab) in Roche's portfolio?

Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

How does Roche contribute to personalized healthcare?

Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.

What recent innovation has Roche introduced in digital pathology?

Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.

What is Roche's approach to advancing haematology treatments?

Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.